A genetic blood disorder that's common in our communities, but rarely discussed. Here's what you need to know.
Thalassaemia is an inherited (genetic) blood disorder that affects the body's ability to produce healthy haemoglobin, the protein in red blood cells that carries oxygen. People with thalassaemia produce less haemoglobin than normal, which can lead to anaemia, fatigue, and in severe cases, life-threatening complications.
It's not contagious. It can only be inherited from both parents passing on a thalassaemia gene to their child.
Thalassaemia is grouped by which globin chain is affected, and by severity. Here are the forms you'll most often hear about.
Caused by missing or faulty alpha-globin genes (we have four, one or more can be affected). Severity ranges from silent carrier (no symptoms) → mild anaemia → Haemoglobin H disease (moderate–severe) → Hydrops Fetalis (most severe, often fatal before birth).
Common in: South Asian, Southeast Asian, Chinese, Middle Eastern, and Mediterranean communities.
The most serious form, usually diagnosed in infancy (between 6 and 24 months). The body produces almost no functional haemoglobin. Without treatment, severe anaemia is life-threatening.
Treatment: lifelong regular blood transfusions (typically every 3–4 weeks) and iron-chelation therapy to manage iron build-up.
With good care: people live full lives, but the daily burden is real.
Carrier status, having one thalassaemia gene and one normal gene. Most carriers have no symptoms or only mild anaemia. They don't need treatment.
Why it matters: two carriers have a 25% chance of having a child with Beta Thalassaemia Major. Knowing your carrier status is important for family planning.
A middle ground, more severe than minor, less severe than major. Most people don't need regular transfusions but may need them occasionally (e.g., during illness or pregnancy).
Care: regular monitoring, sometimes folic acid supplementation, and treatment for complications as they arise.
Symptoms depend on the type and severity. Major usually shows up in infancy; minor often has no symptoms at all.
The most common symptom, from mild tiredness in carriers to debilitating exhaustion in major.
Pallor, especially noticeable in lips, gums, and inner eyelids, a sign of low haemoglobin.
Untreated children with Beta Major may grow slowly, reach puberty late.
In untreated severe cases, bones (especially in the face and skull) can become wider or more brittle.
Yellowing of skin or eyes, caused by red blood cells breaking down faster than normal.
The spleen and liver can become enlarged as they work harder to filter abnormal red blood cells.
Treatment depends on type and severity, from "no treatment needed" for carriers to lifelong transfusion programmes for major.
For Beta Major: typically every 3–4 weeks, lifelong. Maintains haemoglobin levels and allows normal growth and activity.
Regular transfusions cause iron build-up. Chelation drugs (deferasirox, deferiprone, desferrioxamine) remove excess iron and protect the heart, liver, and endocrine system.
Daily supplementation supports red blood cell production, especially helpful for Intermedia and some Minor cases.
The only curative treatment currently available, but it carries risks. Best results when a matched sibling donor is available and treatment is started early.
An emerging treatment showing strong promise. Clinical trials are underway internationally, TASCA NZ tracks progress and advocates for NZ access.
Regular monitoring of heart, liver, bones, endocrine function. Vaccinations against infections. Mental health support.
With modern care, people with Beta Major work, study, travel, partner up, have children, and live well into adulthood. The condition shapes your life but doesn't define it.
TASCA NZ connects whānau with peers, advocates, and clinicians who get it.
Medical information here draws from authoritative guidelines and peer-reviewed literature, including:
